Evaluation of Changes in Functional Status in the Year After Aortic Valve Replacement.


Journal

JAMA internal medicine
ISSN: 2168-6114
Titre abrégé: JAMA Intern Med
Pays: United States
ID NLM: 101589534

Informations de publication

Date de publication:
01 03 2019
Historique:
pubmed: 5 2 2019
medline: 11 2 2020
entrez: 5 2 2019
Statut: ppublish

Résumé

Functional status is a patient-centered outcome that is important for a meaningful gain in health-related quality of life after aortic valve replacement. To determine functional status trajectories in the year after transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR). A prospective cohort study with a 12-month follow-up was conducted at a single academic center in 246 patients undergoing TAVR or SAVR for severe aortic stenosis. The study was conducted between February 1, 2014, and June 30, 2017; data analysis was performed from December 27, 2017, to May 7, 2018. Preoperative comprehensive geriatric assessment was performed and a deficit-accumulation frailty index (CGA-FI) (range, 0-1; higher values indicate greater frailty) was calculated. Telephone interviews were conducted to assess self-reported ability to perform 22 activities and physical tasks at 1, 3, 6, 9, and 12 months after the procedure. Of the 246 patients included in the study, 143 underwent TAVR (74 [51.7%] women; mean [SD] age, 84.2 [5.9] years), and 103 underwent SAVR (46 [44.7%] women; age, 78.1 [5.3] years). Five trajectories were identified based on functional status at baseline and during the follow-up: from excellent at baseline to improvement at follow-up (excellent baseline-improvement), good (high baseline-full recovery), fair (moderate baseline-minimal decline), poor (low baseline-moderate decline), and very poor (low baseline-large decline). After TAVR, the most common trajectory was fair (54 [37.8%]), followed by good (33 [23.1%]), poor (21 [14.7%]), excellent (20 [14.0%]), and very poor (12 [8.4%]) trajectories. After SAVR, the most common trajectory was good (39 [37.9%]), followed by excellent (38 [36.9%]), fair (20 [19.4%]), poor (3 [2.9%]), and very poor (1 [1.0%]) trajectories. Preoperative frailty level was associated with lower probability of functional improvement and greater probability of functional decline. After TAVR, patients with CGA-FI level of 0.20 or lower had excellent (3 [50.0%]) or good (3 [50.0%]) trajectories, whereas most patients with CGA-FI level of 0.51 or higher had poor (10 [45.5%]) or very poor (5 [22.7%]) trajectories. After SAVR, most patients with CGA-FI level of 0.20 or lower had excellent (24 [58.5%]) or good (15 [36.6%]) trajectories compared with a fair trajectory (5 [71.4%]) in those with CGA-FI levels of 0.41 to 0.50. Postoperative delirium and major complications were associated with functional decline after TAVR (delirium present vs absent: 14 [50.0%] vs 11 [13.4%]; complications present vs absent: 14 [51.9%] vs 19 [16.4%]) or lack of improvement after SAVR (delirium present vs absent: 27 [69.2%] vs 31 [81.6%]; complications present vs absent: 10 [62.5%] vs 69 [79.3%]). The findings suggest that functional decline or lack of improvement is common in older adults with severe frailty undergoing TAVR or SAVR. Although this nonrandomized study does not allow comparison of the effectiveness between TAVR and SAVR, anticipated functional trajectories may inform patient-centered decision making and perioperative care to optimize functional outcomes.

Identifiants

pubmed: 30715097
pii: 2723075
doi: 10.1001/jamainternmed.2018.6738
pmc: PMC6439710
mid: NIHMS1000012
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Video-Audio Media

Langues

eng

Sous-ensembles de citation

IM

Pagination

383-391

Subventions

Organisme : NCATS NIH HHS
ID : KL2 TR001100
Pays : United States
Organisme : NIA NIH HHS
ID : K08 AG051187
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG031679
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG048785
Pays : United States
Organisme : NIA NIH HHS
ID : T32 AG023480
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG041785
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001102
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

Ann Intern Med. 1990 Dec 15;113(12):941-8
pubmed: 2240918
PM R. 2015 Jul;7(7):727-735
pubmed: 25661463
JACC Cardiovasc Interv. 2015 Aug 17;8(9):1207-1217
pubmed: 26292584
J Gerontol. 1966 Oct;21(4):556-9
pubmed: 5918309
J Am Coll Cardiol. 2012 Oct 9;60(15):1438-54
pubmed: 23036636
Milbank Mem Fund Q Health Soc. 1976 Fall;54(4):439-67
pubmed: 137366
Annu Rev Clin Psychol. 2010;6:109-38
pubmed: 20192788
N Engl J Med. 2017 Apr 6;376(14):1321-1331
pubmed: 28304219
JAMA Intern Med. 2015 Oct;175(10):1700-2
pubmed: 26237309
Lancet. 2009 Mar 14;373(9667):956-66
pubmed: 19232707
JAMA Cardiol. 2017 Aug 1;2(8):837-845
pubmed: 28658491
J Heart Lung Transplant. 2001 Sep;20(9):1016-24
pubmed: 11557198
Eur Heart J. 2013 Mar;34(9):684-92
pubmed: 23008508
Ann Intern Med. 2016 Nov 1;165(9):650-660
pubmed: 27548070
J Clin Epidemiol. 2003 Jan;56(1):52-60
pubmed: 12589870
JACC Cardiovasc Interv. 2016 Dec 26;9(24):2541-2554
pubmed: 28007203
J Am Coll Cardiol. 2017 Mar 14;69(10):1215-1230
pubmed: 27956264
JACC Cardiovasc Interv. 2017 Feb 13;10(3):268-275
pubmed: 28183466
JAMA. 2013 Nov 20;310(19):2078-85
pubmed: 24240935
Circulation. 2011 Nov 1;124(18):1964-72
pubmed: 21969017
JAMA Surg. 2017 Jun 1;152(6):531-538
pubmed: 28146230
Circ Cardiovasc Qual Outcomes. 2015 Jul;8(4):338-46
pubmed: 26058718
JAMA Cardiol. 2017 Apr 1;2(4):409-416
pubmed: 28146260
Health Qual Life Outcomes. 2006 Nov 24;4:89
pubmed: 17125512
J Am Med Dir Assoc. 2010 Nov;11(9):645-53
pubmed: 21029999
J Gerontol A Biol Sci Med Sci. 2007 Jul;62(7):722-7
pubmed: 17634318
J Am Geriatr Soc. 1999 Jul;47(7):873-8
pubmed: 10404935
J Am Coll Cardiol. 2017 Aug 8;70(6):689-700
pubmed: 28693934
Ann Intern Med. 2014 Feb 18;160(4):243-54
pubmed: 24727842
Pharmacoepidemiol Drug Saf. 2017 Aug;26(8):945-953
pubmed: 28485014
Kardiol Pol. 2017;75(1):13-20
pubmed: 27878802
JAMA Intern Med. 2015 Apr;175(4):512-20
pubmed: 25643002
JACC Cardiovasc Interv. 2015 Feb;8(2):315-323
pubmed: 25700755
J Am Geriatr Soc. 2015 Sep;63(9):1805-11
pubmed: 26280462
J Am Coll Cardiol. 2016 Oct 25;68(17):1868-1877
pubmed: 27765189
Circulation. 2014 Jun 24;129(25):2682-90
pubmed: 24958751
Cochrane Database Syst Rev. 2016 Mar 21;3:CD010876
pubmed: 26998683
J Geriatr Cardiol. 2014 Dec;11(4):279-85
pubmed: 25593575
J Am Coll Cardiol. 2012 Aug 7;60(6):548-58
pubmed: 22818074
Catheter Cardiovasc Interv. 2018 Feb 1;91(2):330-342
pubmed: 28738447

Auteurs

Dae Hyun Kim (DH)

Division of Gerontology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School, Boston, Massachusetts.

Jonathan Afilalo (J)

Centre for Clinical Epidemiology, Division of Cardiology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.

Sandra M Shi (SM)

Division of Gerontology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

Jeffrey J Popma (JJ)

Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

Kamal R Khabbaz (KR)

Division of Cardiac Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

Roger J Laham (RJ)

Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

Francine Grodstein (F)

Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Kimberly Guibone (K)

Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

Eliah Lux (E)

Division of Gerontology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

Lewis A Lipsitz (LA)

Division of Gerontology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH